Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Maze Therapeutics, Inc.NASDAQ: MAZE
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $20M, compared with $0 a year earlier.
Context
- Net receivables amounted to 4.8% of total assets at the end of Q1 FY2026, up 4.8 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Net receivables amounts to 4.8% of total assets for MAZE, versus a peer median of 3.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $239.04M USD | +21.9% | +5.3% | 7.4% | |
| Sep 2026 | $107.53M USD | +29.6% | +68.9% | 12.7% | |
| Mar 2026 | $82.84M USD | +78.3% | +110.2% | 16.4% | |
| Mar 2026 | $20M USD | — | — | 4.8% | |
SEPNSepterna, Inc. | Sep 2026 | $18.88M USD | +61.1% | — | 3.0% |
| Dec 2025 | €9.12M EUR | -25.0% | +219.7% | 3.7% | |
BIOABioAge Labs, Inc. | Mar 2026 | $709K USD | +96.4% | — | 0.2% |
| Mar 2026 | $0 USD | -100.0% | +46.5% | 0.0% | |
| Peer median (excluding MAZE) | — | +29.6% | +68.9% | 3.7% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.